Akston Biosciences
Anshul Krishnan has a diverse work experience that showcases their expertise in the biotechnology and healthcare industries. In 2018, they worked as a Student Researcher at ASU Human Mobility Lab, where they conducted research studies on fall prevention strategies and therapeutic devices for stroke survivors. This role required in-depth knowledge of biomechanics, neural rehabilitation techniques, and data processing software. In the same year, they also had a short-term role with BioCare Tanzania, where they performed recalibration and servicing duties.
In 2020, Anshul co-founded CarciNoMatch, highlighting their entrepreneurial skills. As a co-founder, they played a crucial role in the establishment and growth of the company.
Anshul furthered their entrepreneurial pursuits as a Bioentrepreneurship Fellow at Entrepreneurship at Cornell from 2022 to 2023. This fellowship allowed him to gain valuable experience in the field of bioentrepreneurship.
Their most recent work experience is as a Business Development Associate at Akston Biosciences Corporation, starting in 2023. In this role, Anshul utilizes their business acumen to support the company's growth and development.
Overall, Anshul Krishnan's work experience demonstrates their passion for biotechnology, entrepreneurship, and the healthcare industry.
Anshul Krishnan's education history begins with earning a Bachelor of Engineering (BE) degree in Biomedical Sciences and Biomedical Engineering from the Ira A. Fulton Schools of Engineering at Arizona State University. This degree was obtained between the years 2017 and 2021.
After completing the undergraduate program, Anshul pursued further education at Cornell University. Here, between 2021 and 2022, Anshul earned a Master of Engineering (MEng) degree with a specialization in Bioengineering and Biomedical Engineering.
Continuing their academic journey, Anshul is currently enrolled at the Cornell Johnson Graduate School of Management, pursuing a Master of Business Administration (MBA) degree. This program began in 2022 and is expected to be completed in 2023.
In addition to their academic pursuits, Anshul also obtained certification in IRB and Engineering Ethics from the CITI Program, a Division of BRANY, in July 2019.
This person is not in the org chart
This person is not in any teams
Akston Biosciences
Akston Biosciences Corporation leverages its novel fusion protein platform to develop and manufacture new classes of biologics, including vaccines, ultra-long-acting insulins, and autoimmune disease therapies.